New Delhi, India-- (SBWire) -- 12/01/2017 --Friedreich's Ataxia a rare inherited autosomal recessive disorder that causes nervous system damage and movement problems. It is caused by a mutation in a gene labeled frataxin (FXN). Over time this deficiency causes the aforementioned damage, as well as frequent fatigue due to effects on cellular metabolism. Friedreich's ataxia is the most common of the autosomal recessive ataxias.
Currently, there are more than 20 active pipeline products undergoing development in different clinical stages. Some drugs that are currently in the pipeline Phase II includes RT001 (Retrotope), Epicatechin (Cardero Therapeutics), ABT-RTA 408 (Reata Pharmaceuticals), JOT101 (Jupiter Orphan Therapeutics), TAK-831 (Takeda), and Vatiquinone (Edison Pharmaceuticals).
The latest report of DelveInsight, "Friedreich's Ataxia – Treatment Algorithm and Competitive Landscape, 2017", has covered a detailed description of Diagnosis, Management and Treatment in Europe, US and Other Countries. Information about all the collaborations, financing and licensing deals. Complete Pipeline drugs profiling covering each and every phase of development. Not only pipeline drugs but the detailed description of the pre-clinical, discovery and inactive products is also provided in the report. Treatment algorithm and competitive is the main focus of this report making it a complete package for understanding the complete market scenario. Details about all the possible market drivers and barriers are also provided to better understand the areas of improvement and to plan the strategies accordingly.
Companies Covered:
-Retrotope
-Cardero Therapeutics
-Reata Pharmaceuticals
-Jupiter Orphan Therapeutics
-Takeda
-Edison Pharmaceuticals
-Shire
And many others……………….
Fragile X Syndrome is one of the most common cause of inherited mental impairment. It can range from learning disabilities to more severe cognitive or intellectual disabilities. Fragile X syndrome is caused by an over repetition of a specific DNA segment which leads to the shutdown of the FMR1 gene.
Currently, there are more than 15 drugs in the pipeline development phase for the treatment of Fragile X Syndrome. Out of all the pipeline drugs, ZYN-002 (Zynerba Pharmaceuticals) is the most promising drug candidate. It is expected to have a positive impact on the market after getting launched in 2020-2021. Currently, there are 4 drugs in Phase II of development. Market size is expected to grow rapidly after 2020 with the launch of some promising drugs and is expected to reach around USD 800 million by 2025.
The latest report of DelveInsight, "Fragile X Syndrome – Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025", has covered detailed information about the treatment algorithm. Complete pipeline drugs profiling is provided to better understand the mechanism of action, drug target, and other details about the drugs. Epidemiology details for 7MM (2015-2025) are also provided in this report to understand the exact ground scenario of the indication. Total market size for the 7MM is also provided to give better insight into planning the strategies accordingly. Information about the market drivers and barriers is also covered to identify the areas of improvement and grab the maximum out of the existing and the future market.
Companies Covered:
-Zenerba
-Marinus
-Alcobra
-Neuren Pharmaceuticals
-Advanced Medical Projects
And many others………………….
Niemann-Pick disease type C (NPC) is very different than Type A or B (ASMD). NPC Patients are not able to metabolize cholesterol and other lipids properly within the cell. Consequently, excessive amounts of cholesterol accumulate in the liver and spleen and excessive amounts of other lipids accumulate in the brain. NPC causes a secondary reduction of ASM activity, which led all three types to be considered forms of the same disease.
The latest report of DelveInsight, "Niemann-Pick disease type C (NPC) - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025", has covered detailed information about the treatment practices, prevalence and epidemiology details for 7MM. The report has covered the marketed drug profiling and complete information about the emerging therapies. Total market size for 7MM (2015-2025) is also provided to better understand the market scenario and to identify the potential for growth. All the market drivers and barriers are also covered in this report to plan the strategies accordingly. The report has provided detail about all the unmet needs in the NPC market.
Reasons to buy:
-The report will help in developing business strategies by understanding trends shaping and driving the market.
-To understand the future market competition in the market and Insight reviews of the key market drivers and barriers.
-Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
-In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.
Orphan Insights: Friedreich's Ataxia: Fragile X Syndrome: Niemann-Pick Disease Type C (NPC)
DelveInsight's Report provides In-Depth information about the market. Customized reports provide details specific to the needs of a client to remain ahead of the competitors.